News and Press Releases
Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration
Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties 7 January 2025 -- California, US -- Capsida Biotherapeutics today announced that AbbVie has...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
From Discovery Park to Merck, Top Industry Players to Showcase at London Biotechnology Show 2025
7 November 2024 -- London, UK -- Back for its second year, the London Biotechnology Show (#LBS25) gathers prominent biotech leaders, policymakers, and industry enthusiasts for an unparalleled showcase. Attendees...
Category: Biotechnology, Other, Pharmaceutical
Posted: November 7, 2024
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
5 November 2024 –Tokyo, Japan and London and Cardiff, UK – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio...
Category: BioManufacturing
Posted: November 6, 2024
PTC Therapeutics to Participate at Upcoming Investor Conferences
4 November 2024 -- New Jersey, US -- PTC Therapeutics, Inc today announced that the company will present a company overview at the following conferences: UBS Global Healthcare ConferenceWednesday, Nov....
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: November 4, 2024
PTC Therapeutics Inc. 100 Corporate Court South Plainfield, NJ 07080-2449
Travere Therapeutics to Present at Upcoming Investor Conferences
4 November 2024 -- California, US -- Travere Therapeutics, Inc today announced that company management will present in the following upcoming investor conferences in November: Guggenheim Securities Healthcare Innovation ConferenceMonday, November 11,...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 4, 2024
The Largest Network of Research Sites Vetted to Execute Complexities of Cell & Gene Therapy (CGT) Trials Now Includes 1,500 Sites
Advarra’s Gene Therapy Ready (GTR) global site network expands to better support and accelerate the rapidly growing number of CGT investigational new drugs through approval 3 October 2024 -- Maryland,...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 3, 2024
ViroCell Biologics signs Master Services Agreement with prominent NCI-designated cancer centre
MSA enables collaboration on full suite of ViroCell’s viral vector manufacturing services to accelerate the cancer centre’s clinical development of novel gene-modified cell therapies Agreement follows ViroCell’s successful GMP manufacture...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: July 22, 2024
Mogrify appoints Dr Jonathan Appleby as chief scientific officer
Strategic hire bolsters executive leadership team as company progresses multiple therapeutic programmes toward and into clinical development 15 July 2024 – Cambridge, UK – Mogrify, a regenerative medicine company developing...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 15, 2024
Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters
Annogen to develop immune cell-specific human promoters for certain Orchard pre-clinical programmes 4 June 2024 -- Amsterdam, The Netherlands -- Annogen, a company with expertise in bespoke promoter design and...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: June 4, 2024
Bionova Scientific announces plans for new Plasmid DNA GMP facility
Facility in The Woodlands, Texas, US, to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025 3 June 2024 -- California, US --...
Category: BioManufacturing, Manufacturing and Packing, Pharmaceutical
Posted: June 3, 2024
Cellular Origins and Cell and Gene Therapy Catapult collaborate to demonstrate universal automation of CGT manufacturing
Partnership to develop and implement Cellular Origins’ robotic platform Constellation for universal automation of CGT manufacturing at CGT Catapult’s Stevenage Manufacturing Innovation Centre, UK 29 May 2024 -- Cambridge, UK,...
Category: BioManufacturing, Biotechnology, Drug Discovery
Posted: May 29, 2024
Successful Conclusion of London Biotechnology Show, Leaves Attendees Highly Satisfied
10 May 2024 -- London, UK -- The curtain has closed on the debut London Biotechnology Show 2024, leaving attendees thoroughly impressed by the seamless delivery of promised content and...
Category: Biotechnology
Posted: May 10, 2024
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at Six Weeks
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing phase 1/2...
Category: Biotechnology, Clinical Trials
Posted: May 8, 2024
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG
First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, New Jersey, US
With the recent FDA approval of LYFGENIA, developed by bluebird bio, Minaris Regenerative Medicine North America is now supporting a commercial cell and gene therapy (CGT) product The first commercial...
Category: BioManufacturing, Biotechnology
Posted: May 8, 2024
